The Hybrid Capture 2 (HC2) test targets 13 human papillomavirus (HPV) types. Here, cross-reactivity with non-HC2-targeted HPV types is described. We aimed to define the proportion of HC2-positive women who had negative results with HC2-targeted HPV types and estimate its determinants and impact on women's health management. The New Technologies for Cervical Cancer (NTCC) trial was followed in two predetermined phases. Women in the experimental arm were tested for the presence of HPV DNA by HC2 following a sample collection in PreservCyt (first phase) or Digene specimen transport medium (STM) (second phase). HPV genotyping was performed on DNA samples from HC2-positive women by PCR with GP5 ؉ /GP6 ؉ primers and reverse line blot (RLB) hybridization. Untyped samples were submitted to direct sequencing or restriction fragment length polymorphism. Multivariate logistic regression analysis estimated the adjusted odds ratios ( C ervical screening has the main purpose of decreasing the burden of cervical cancer by detecting and treating highgrade cervical intraepithelial neoplasia (CIN). Highly sensitive and specific tests have been established to identify the human papillomavirus (HPV) infections that are associated with detectable CIN. Double-testing studies (1) and randomized controlled trials (RCTs) (2-6) have highlighted Hybrid Capture 2 (HC2) as a highly sensitive test (Ͼ95%) (7) for detecting highgrade CIN. Conversely, the HC2 test showed lower clinical specificity than did cytology (90%) (7). Most of the false positives that make the test specificity so low are due to women who are actually infected by a high-risk HPV type but who have not developed high-grade lesions and, in most cases, will never develop cervical lesions (8). To date, this drawback has been overcome by the introduction of triage procedures that limit the referrals of HPV-positive women for unnecessary diagnostic procedures.
C
ervical screening has the main purpose of decreasing the burden of cervical cancer by detecting and treating highgrade cervical intraepithelial neoplasia (CIN). Highly sensitive and specific tests have been established to identify the human papillomavirus (HPV) infections that are associated with detectable CIN. Double-testing studies (1) and randomized controlled trials (RCTs) (2-6) have highlighted Hybrid Capture 2 (HC2) as a highly sensitive test (Ͼ95%) (7) for detecting highgrade CIN. Conversely, the HC2 test showed lower clinical specificity than did cytology (90%) (7) . Most of the false positives that make the test specificity so low are due to women who are actually infected by a high-risk HPV type but who have not developed high-grade lesions and, in most cases, will never develop cervical lesions (8) . To date, this drawback has been overcome by the introduction of triage procedures that limit the referrals of HPV-positive women for unnecessary diagnostic procedures.
It has been claimed that HC2 also has analytical false-positive results. HC2 includes a cocktail of probes designed to detect 13 HPV types, HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, and -59, which are classified by the International Agency for Research on Cancer (IARC) (9) as carcinogenic with sufficient evidence (group 1), and HPV-68, which is classified as probably carcinogenic (group 2A). Some studies have shown cross-reactivity with other HPV types that are phylogenetically related to the targeted genotypes (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) .
Increasing analytical false positives were observed with decreasing viral load, as measured by the ratio between the relative light units (RLU) of the specimen and the RLU of a positive cutoff (PC) consisting of 1 pg/ml of HPV DNA (RLU/PC ratio) (11, 15, (20) (21) (22) . In addition, lower reproducibility of the HC2 results between laboratories (23) and lower agreement between HC2 and PCR with the MY09 to MY11 primers when followed by dot blot hybridization (19) was reported with samples collected in PreservCyt (which is used for liquid-based cytology) than in those collected in the Digene standard transport medium (STM); this suggests a role of the transport medium in the analytical accuracy of HC2. The large size of the New Technologies for Cervical Cancer (NTCC) trial, in which samples were collected in both the Preserv-Cyt and STM transport media and were stored, and the active follow-up of the women involved, provide a suitable frame for accurate estimates of these parameters.
The objective of this study was to estimate the frequency of analytical false-positive results of HC2, its determinants, and their impacts on clinical accuracy.
MATERIALS AND METHODS
Study population and sample collection. The New Technologies for Cervical Cancer (NTCC) screening study was a randomized controlled trial conducted in 9 Italian centers that compared cytology to an experimental arm during two subsequent phases, the first with cotesting for HPV DNA by the Hybrid Capture 2 (HC2) (Digene-Qiagen, Hilden, Germany) test and liquid-based cytology and the second with stand-alone HC2 testing (2, 4, 24) . The study was approved by the local ethics committees of the participating centers. The randomized clinical trial registration number is ISRCTN81678807. Women were considered to be HC2 positive if their RLU/PC ratio was Ͼ1, the cutoff that was recommended by the manufacturer. Seventy-four percent of eligible women were accepted for randomization in the trial, and 47,369 were randomized to the experimental arm.
The storage of residual cell samples after a positive HC2 test was set up during both study phases in Florence, Padua, Trento, and Turin, while in Bologna, Imola, Ravenna, and Viterbo, it was only performed during the second phase, and it was not done at all in Verona. Of 37,367 women randomized to the experimental arm in these time periods and centers, 37,077 had valid HC2 results and 3,033 of them were found to be HPV positive. Only the first HC2-positive sample for each woman was genotyped. Samples were not available for 113 HPV-positive women, leaving 2,920 samples for genotyping. Among them, 1,264 (43%) were originally collected in PreservCyt (Cytyc Corporation, Marlborough, MA) and processed with a manual conversion procedure (HC2 sample conversion kit; Digene-Qiagen, Hilden, Germany) before performing the HC2 test during phase 1, and 1,656 (57%) were collected in the Digene STM (DigeneQiagen, Hilden, Germany) solution during phase 2. Samples from Bologna, Imola, Ravenna, and Viterbo represented 25.7% (425/1,656) of those obtained in phase 2. Residual cells from samples collected in PreservCyt were stored at Ϫ80°C following double phosphate-buffered saline (PBS) washing to remove methanol; aliquots (400 l) from samples collected in STM were taken before HC2 testing and stored at Ϫ80°C in their own solution.
DNA extraction. DNA was obtained from one of the two stored aliquots of PreservCyt and STM samples by purification through the QIAamp DNA minikit (Qiagen, Hilden, Germany) according to the manufacturer's instructions, with a final elution in 80 to 100 l of Adams-Evans (AE) elution buffer. DNA adequacy was checked by PCR amplification of a 268-bp fragment of the ␤-globin gene (25) in all the HC2-positive samples that gave negative results at genotyping.
Genotyping assays. Genotyping was conducted in the molecular laboratories of 4 out of the 9 centers involved in the NTCC trial: Florence (where they also typed the samples from Viterbo), Padua, Trento (where they also typed the samples from Bologna, Imola, and Ravenna), and Turin. Methods were optimized and protocols shared to ensure equivalent accuracy and efficiency of the results.
Genotyping was performed by using the Digene HPV genotyping RH kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions, with slight modifications (26) . The assay targets 18 high-risk HPV types (27) , which include types assigned by the IARC to group 1 (HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, and -59), group 2A (HPV-68), and group 2B (HPV-26, -53, -66, -73, and -82) (9) . Briefly, following a PCR assay with GP5 ϩ /GP6 ϩ consensus primers (28), a reverse line blot (RLB) hybridization assay was performed. An HPV-positive control and two negative PCR controls (a purified DNA HPV-negative sample and a DNA-free sample) were included in each PCR run. The sensitivity limit of the assay obtained in our laboratories that participated in the WHO HPV LabNet Proficiency study (29) was 50 copies/5 l for HPV-16, -18, -31, -33, -35, -45, -56, and -66, and 500 copies/5 l for HPV-39, -51, -52, -58, -59, -68a, and -68 (ME 180). Ten microliters of PCR biotinylated products was denatured and hybridized at 50°C with type-specific oligonucleotide probes immobilized as parallel lines on nitrocellulose membrane strips. The hybrids were detected with alkaline phosphatase-streptavidin conjugate and substrate (5-bromo-4-chloro-3-indolylphosphate and nitroblue tetrazolium), resulting in a purple precipitate at the positive probe lines. After 30 min, this reaction was stopped by washing the mixture in distilled water. After drying, the strips were analyzed visually from an interpretation grid supplied with the kit; the presence of a clearly visible line was considered to be a positive result.
All samples that remained untyped by this method but which had shown a visible amplicon using gel electrophoresis following PCR with the consensus primers were submitted to further analytical procedures to increase the efficiency of typing, with the aim of identifying the true proportion of false positives for any HPV type. Restriction fragment length polymorphism (RFLP) (30) and direct sequencing procedures were performed for untyped samples, and nested PCR was performed for the samples that remained HPV negative (26) in order to identify the samples with no HPV present.
CIN assessment. All HC2-positive women were referred to colposcopy except women aged 25 to 34 years at recruitment during phase 1. If HC2 was positive but cytology was normal, the latter group was referred to colposcopy only if HC2 was confirmed as positive or cytology became abnormal after 1 year. All colposcopically suspected areas were biopsied. Biopsy samples of women with a CIN diagnosis were reviewed blindly to test results (31) .
Statistical methods. Each sample was assigned, considering the HPV genotypes that can be detected by any method, to one of five classes: class a if at least one of the types targeted by HC2 was detected, also when in coinfection with other HPV types, class b if no HC2-targeted type was found but at least one of the HPV types classified by the IARC in group 2B was detected, i.e., one that is possibly carcinogenic to humans (HPV-26, -53, -66, -67, -70, -73, and -82) and types with phylogenetic similarity to types with sufficient or limited evidence for cervical cancer in humans (HPV-30, -34, -69, -85, and -97) (9) , and when in coinfection with other HPV types, class c if only HPV types not targeted by HC2 and not classified as 2B were present, class d if there was untyped HPV only, and class e if no HPV DNA was detected. The proportion of samples in class a among all HC2-positive samples represented the analytical positive predictive value (PPV) of HC2. Its confidence intervals were computed based on the exact binomial distribution. An approximate analytical specificity was computed with the assumption that all HC2-negative samples were true negatives (32) . The number of false positives was computed applying the observed PPV in genotyped samples to all HC2-positive women. Given the high analytical sensitivity of HC2 and the relatively low frequency of HC2-targeted HPV infections in the studied population (4), such an approximation is plausibly very good.
The presence of HC2-targeted types (class a) and of any HPV type (classes a to d) among HC2-positive samples was cross-tabulated with age, RLU/PC ratio, and type of transport medium. In addition, in order to investigate the determinants of cross-reactivity with non-HC2-targeted HPV types, we studied the presence of the HPV types targeted by HC2 (class a) among the samples in which any HPV was detected (classes a to d). Odds ratios adjusted for age, RLU/PC ratio, type of transport medium, and laboratory that performed genotyping were obtained by unconditional logistic regression analysis. In these models, age and the log of the RLU/PC ratio were considered to be linear variables. Wald-type confidence intervals were computed.
The proportion of histologically confirmed CIN2 and CIN3 ϩ detected in each class defined above and the clinical PPV of each class for such lesions were computed. Confidence intervals were computed based on the exact binomial distribution. In addition, in order to understand how much the effect of the type of transport medium and viral load on clinical PPV was the result of analytical inaccuracies, we computed their PPV, both including and excluding analytical false positives.
RESULTS
The overall HC2 positivity rate in the study population was 8.2% (3,033/37,077); the proportion was higher in women aged Ͻ35 years (13.57%) (P Ͻ 0.0001) and during the first phase of the NTCC trial when PreservCyt transport medium was used (8.8%) (P Ͻ 0.0001). Genotyping results are reported in Table 1 . Out of 2,920 available HC2-positive DNA samples, 2,310 (79.1%) were positive for one or more of the 13 HPV types targeted by HC2 (class a), while 301 (10.31%) were negative for HC2-targeted types but contained at least one level 2B HPV type (class b), 62 (2.12%) were positive for other HPV types only (class c), 33 (1.13%) remained untyped with all the methods employed (class d), and 214 (7.33%) were negative to all the HPV detection methods applied (class e). Therefore, 610/2,090 (20.9%) samples did not contain HC2-targeted types, although 64.9% of them (396) did contain HPV DNA. The analytical positive predictive value (PPV) of HC2 was 79.1% (95% CI, 77.6 to 80.6). When we also considered the samples with group 2B types and those that were untyped to be true positives, the PPV increased to 90.6% (95% CI, 89.5 to 91.6). The approximate analytical specificity of HC2 for the targeted HPV types was 98.2%. The RLB assay, performed directly following PCR, allowed for the genotyping of The proportion of samples with HC2-targeted types, and with any HPV type among HC2-positive samples, significantly decreased with increasing age at recruitment and strongly with the use of the PreservCyt over the STM transport solution (Tables 2  and 3 ). These proportions also significantly and strongly increased with increasing viral load (RLU/PC). They were very low, with RLU/PC values close to the cutoff (RLU/PC Ͻ2, but still for values Ͻ4), particularly when the PreservCyt solution was used. Using the PreservCyt solution, Ͻ60% of the samples with an RLU/PC ratio of Ͻ4 contained HC2-targeted HPV types (Table 2) , and a higher proportion of samples with no HPV detected (class e) was found than when the STM solution was used ( Table 3) . The ORs for all determinants were less extreme when the presence of HC2-targeted types was the endpoint and more extreme when the presence of any HPV DNA was the endpoint. However, this change was particularly large for the type of transport medium: the OR was 1.52 (95% CI, 1.25 to 1.84) for the presence of HC2-targeted types and 2.93 (95% CI, 2.04 to 3.91) for the presence of any HPV DNA (Table 3) . Conversely, the proportion of samples with HC2-targeted types among the samples with any HPV type were only affected by viral load, while it was not associated with age and type of transport medium (Tables 2 and 3). Results related to type of transport medium were virtually unchanged when excluding the centers that collected samples only in phase 2 (data not shown).
Histologically confirmed high-grade lesions were detected at recruitment in 204 of the HC2-positive studied women, 117 with CIN2 and 87 with CIN3 (Table 4) . Ten of these occurred in women without HC2-targeted types. Of these 10 women (including 2 with CIN3), four had HPV types classified by IARC as group 2B, another four had only other HPV types, and two had no HPV DNA detected. If there were no analytical false-positive results, 194 high-grade lesions would have been detected, 109 being CIN2 and 85 being CIN3; therefore, 4.9% (95% CI, 2.38% to 8.88%) of CIN2 ϩ and 2.3% of CIN3 (95% CI, 0.2% to 8.1%) would have been missed. In this case, however, the clinical PPV for histologically confirmed CIN2 ϩ of HC2 positivity would have increased from 7.0% (95% CI, 6.1 to 8.0) to 8.4% (95% CI, 7.3 to 9.6). The PPVs for CIN2 ϩ (1.6% [95% CI, 0.8 to 3.0]) and especially for CIN3 (0.3% [95% CI, 0.004 to 1.2]) were very low in false-positive cases and surprisingly were lower among women with group 2B types than in women with only noncarcinogenic types (Table 4) . Two women with CIN2 and none with CIN3 had samples containing HPV-53 out of 76 women with infections by that type. Almost all the differences in PPVs for CIN2 ϩ between women with samples taken in PreservCyt versus STM disappeared when excluding the cases without HC2-targeted types. However, this exclusion affected only marginally the difference in PPVs between women with an RLU/PC ratio of Ͻ4 versus a ratio of Ն4 (Tables 4  and 5 ).
DISCUSSION
In our study, 20.9% of 2,920 HC2-positive samples did not contain HC2-targeted HPV types and can be considered to be analytical false positives. This happened despite an approximately 98.2% analytical specificity because of the low prevalence of targeted types in the study population. About half of those samples contained HPV types with limited (IARC group 2B) evidence of carcinogenicity. However, the clinical value of these positive tests is small, given the low probability of detecting CIN2 and especially CIN3 in these women, including those with HPV-53. Overall, the loss in clinical sensitivity that resulted by missing the HPV types not targeted by HC2 would be small, in line with previous reports (15) suggesting that efforts to increase the number of targeted HPV types (i.e., HPV-53, HPV-66, and others) in HPV screening tests would not significantly improve clinical sensitivity. In addition, the probability of progression of these CINs is unknown, and histological false positives cannot be excluded (31, 33) . Conversely, improvements in analytical specificity would have a nonnegligible impact in reducing unneeded triage and/or colposcopy.
Of the 610 false-positive samples that contained non-HC2-targeted HPV types, 64.9% contained HPV DNA and could therefore possibly result from cross hybridization, while the 30.1% of samples in which no HPV DNA could be detected even following intensive search were plausibly caused by other technical problems. However, the proportion of false positives that is actually caused by cross-hybridization might be slightly Ͻ64.9% because false positivity caused by non-cross-hybridization problems might also have occurred in samples containing non-HC2-targeted HPV types.
Also, in our sample series, the large majority of cross-hybrid- a RLU/PC ratio is the ratio between the specimen relative light units (RLU) and the positive cutoff (PC) value of 1 pg/ml of HPV DNA, a relative measure of the HPV viral load in the sample. izations occurred with types HPV-53, HPV-66, and HPV-70, which are phylogenetically related to the HPV types included in HC2 (34, 35) , which is consistent with observations in previous studies (10-13, 16, 20) . Increasing age (as was also observed in the ARTISTIC study [20] ), the use of the PreservCyt transport medium, and a low RLU/PC ratio were significantly associated with false-positive HC2 results. The two latter trends especially have practical relevance.
The use of the PreservCyt transport medium instead of STM does not seem to be a determinant of cross-hybridization but is plausibly an important cause of the remaining false-positive results obtained with HC2. Indeed, in this study, PreservCyt use was not associated with a lack of HC2-targeted types among samples that contained some HPV DNA, while it showed a very strong association with the absence of any HPV DNA. In the ARTISTIC study where PreservCyt was used, no HC2-targeted type was detected in some 30% of samples from HC2-positive women (20) and, interestingly, in most of them, no HPV could be detected (with a less-intensive approach than ours). PreservCyt samples need preanalytical treatment to achieve suitability for performance with the HC2 test. Such a preanalytical step, when carried out using a manual conversion system (sample conversion kit; Digene-Qiagen), can be critical since residual traces of undenatured DNA may generate results in a gray zone with RLU/PC ratios between 1 and 2.5 and an increase in borderline false-positive results (19, 23) .
New technologies that allow raw DNA extraction (QIAsymphony, Qiagen) are now available to escape the manual conversion step that precedes the HC2 assay. PreservCyt allows for the performance of HPV testing and liquid-based cytology on the same material, which represents an advantage if cytological triage for HPV-positive women or cotesting is applied. Its effects on false-positive HC2 results should, however, be considered when the manual conversion procedure is used. Among women aged Ͼ35 years, a lower HC2 prevalence was found in phase 2 of NTCC study when STM was used (5.8%) than in phase 1 when PreservCyt was used (7.1%), while the PPV of HC2 positivity for highgrade CIN was higher in phase 2 (7.2%) than in phase 1 (6.6%) (2, 4). These differences might largely be the result of a lower proportion of analytical false-positive results with the use of STM. Indeed, in our study, the differences in PPV by the type of transport medium almost disappeared when excluding women with falsepositive analytical results.
A decreasing RLU/PC ratio was strongly associated with increasing frequency of false-positive results. As a low RLU/PC ratio was associated with both lack of any HPV and the absence of HC2-targeted types among samples with HPV, both cross-hybridization and other mechanisms seem to be relevant. In all RCTs that used HC2, increasing the cutoff from 1 to 2 or 4 RLU/PC decreased the sensitivity only marginally, while the proportion of HC2-positive women without high-grade CIN was strongly reduced. Part of this effect might be due to the fact that about 40% of cases collected in PreservCyt and 30% of those collected in STM with an RLU/PC ratio between 1 and 4 did not contain the testtargeted HPV types. However, most of this effect seems to be related to viral load. Indeed, in our study, the differences in PPV for high-grade CIN between women with high and low RLU/PC ratios remained almost unchanged when excluding analytical false positives. The HC2 manufacturer currently recommends a retesting procedure of PreservCyt samples when HPV-positive results fall into a gray zone with RLU/PC ratios between 1 and 2.5, with an indication to repeat the HC2 test once if the second result is concordant with the first, or twice if discordant. In our setting, the gray zone was not considered since the NTCC trial started in 2002, when the retesting procedure was not yet recommended. This procedure has also an impact on costs, which is worthy of consideration. This study has strengths and limitations. The studied samples are highly representative of those coming from a general screening population. In addition, intensive analytical efforts with the hierarchical application of different approaches was done by laboratories conducting internal-external quality assurance, in order to identify all infections present. However, we cannot exclude the possibility that some of the disagreements between the HC2 and genotyping were not due to HC2 false positives but to analytical inaccuracies of the genotyping process (problems in DNA preservation are not plausible, as all negative samples were positive for beta-globin amplification). The potential underestimation of multiple infections also has to be taken into account due to the use of GP5 ϩ /GP6 ϩ primers in the assay we employed (36) . These factors might have led to an overestimation of HC2 false positives and possibly to misclassifications in their subcategories. Nevertheless, as data showed a strong association of false positives and subgroups with plausible causal determinants, it is unlikely that the above-mentioned overestimation and misclassifications would have a significant impact on results.
Confounding by plausible determinants was controlled by the adjustment of ORs through logistic regression analysis. Some centers were considered only in phase 2 (when STM was used); however, results on type of transport medium were virtually unchanged when excluding these centers.
Finally, it must be kept in mind that only the impact of HC2 cross-reactivity on the PPV for the detection of prevalent CIN2
ϩ , but not its prognostic value on subsequent lesions, was considered.
In conclusion, in the NTCC study, some 20% of HC2-positive samples did not contain the targeted HPV types. About two-thirds of them resulted from cross-hybridization, especially with HPV-53, HPV-66, and HPV-70. New validated screening tests include in their panel HPV-66, and positivity found with its presence probably compensates in comparative studies for the cross-hybridization of HC2. However, including the detection of HPV-53, HPV-66, and HPV-70 results in very little gains in sensitivity for high-grade CIN. Using STM instead of PreservCyt (followed by a manual conversion procedure) as the transport medium and/or increasing the cutoff as previously suggested (37) reduces the analytical false-positive rate and increases the PPV for highgrade CIN.
